Stocks Health care MGX
NASDAQ · Health careMetagenomi Therapeutics, Inc. (MGX)
It posted a net loss of $93.5M. In fiscal 2025 capital spending exceeded operating cash flow by $89.5M. At June 30, 2026 it held $39M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
What Metagenomi Therapeutics, Inc. does
Metagenomi Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MGX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $25.2M | -$87.9M | -$2.36 | -$89.5M |
| 2024 | $52.3M | -$78.1M | -$2.36 | -$112.2M |
| 2024 | $44.8M | -$68.3M | -$20.05 | -$101.2M |
Latest SEC filings
What Metagenomi Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026
- September 10, 2026Passive stake (5% or more) SCHEDULE 13G
- August 10, 2026Quarterly report 10-Q · period to June 30, 2026
- August 10, 2026
- June 10, 2026
- May 11, 2026Quarterly report 10-Q · period to March 31, 2026
- May 11, 2026
- April 27, 2026
- April 27, 2026Additional proxy material DEFA14A
- April 27, 2026Proxy statement DEF 14A
Questions about MGX
What does Metagenomi Therapeutics, Inc. do?
Metagenomi Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker MGX.
Is Metagenomi Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $93.5M.
When did Metagenomi Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 22, 2026.
Similar companies
Follow MGX
Get an email when Metagenomi Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MGX: get an email when it filesWhere the numbers come from
Financial figures are the values Metagenomi Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.